Mind Medicine (MindMed) Inc (NEO:MMED)(OTCQB:MMEDF), the leading drug development company for psychedelic-inspired medicines, said Monday it is evaluating an expanded US investor base through an up-listing on the Nasdaq Capital Market.
As part of the up-listing strategy in the US, the company said it has submitted an application to list its subordinate voting shares on the Nasdaq.
The listing of MindMed's shares on the exchange will be subject to a number of regulatory requirements, including review of the company and acceptance for listing by Nasdaq. There can be no assurance that Nasdaq acceptance will be granted.
New York-based MindMed said it has appointed Canaccord Genuity Corp as financial advisor to assess the viability of a potential up-listing to Nasdaq and also help to evaluate M&A opportunities available to the company.
"The psychedelic medicine industry is maturing and expanding rapidly, and we want to grow with it,” said co-founder and co-CEO JR Rahn in a statement.
“We look forward to working with Canaccord Genuity to evaluate the opportunity for an up-listing on NASDAQ and help us navigate M&A opportunities now available to the company."
Contact the author: firstname.lastname@example.org
Follow him on Twitter @PatrickMGraham